The US Food and Drug Administrationmay authorise the use of the Pfizer and BioNTech vaccine in the age group even though it did not meet a key target in a clinical trial of two- to four-year-olds. The drugmakers said they submitted data supporting authorisation at the request of the FDA in order to address an urgent public health need in the age group.
Outside advisors to the FDA are scheduled to meet on February 15 to discuss whether to recommend the regulator to authorise the vaccine. The roll out of the vaccine for children under the age of 5, the only age group not yet eligible for the shots, is set to begin less than a week after the meeting.
According to the CDC document, the government is planning to ship an initial 10 million doses of the Pfizer/BioNTech vaccine to states and other entities before the end of February, should the FDA authorise their use.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)